# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target fro...
Use of proceeds to fund working capital needs stemming from Novocure's anticipated launch in non-small cell lung cancer and...
NovoCure (NASDAQ:NVCR) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.42) by 1...
Novocure (NASDAQ:NVCR) today announced the results of the METIS phase 3 clinical trial in brain metastases from non-small cell ...
Piper Sandler analyst Jason Bednar reiterates NovoCure (NASDAQ:NVCR) with a Overweight and raises the price target from $25 ...